ESSA Pharma Inc.

ESSA Pharma Inc.: Focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Ph 1 clinical trial in men with metastatic castration-resistant prostate cancer whose tumors have progressed on current standard-of-care therapies. Initial data for Ph 1 monotherapy study of EPI-7386 is expected in 1H 2022. The company has also established clinical collaborations with JNJ, Astellas, and Bayer to evaluate EPI-7386 in combination with conventional anti-androgens. Combo trials remain on track to begin in Q4 2021 with RP2D already established.
Based in...
North America
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology
Public, USA
Market Cap
100MM - 500MM
999 West Broadway Street Suite 720
Vancouver, BC BC V5Z 1K5

Company Participants at Solebury Trout Virtual Management Access Event 2021

David Parkinson
ESSA Pharma Inc., President/CEO
Dr. Parkinson has been ESSA’s President and Chief Executive Officer since 2016 and has been a member of ESSA’s Board of Directors since 2015. Dr. Parkinson has more than 30 years of experience in clinical oncology development. Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson currently serves as Director on the Boards of CTI Biopharma, Inc. and 3SBio Inc and is a Co-Founder and Director of Refuge Biotechnology, Inc. Dr. Parkinson has held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, has authored over 100 peer-reviewed publications and is a recipient of the FDA’s Cody Medal. Dr. Parkinson received an M.D. from the University of Toronto.

Top 10 Holders of ESSA Pharma Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Bellevue Asset Management AG 11.45 5,034,814 46.92 13F 9/30/21
Janus Henderson Group Plc (Subfiler) 7.91 3,477,844 32.41 13F 9/30/21
Clarus Ventures LLC 7.51 3,303,103 30.78 13F 9/30/21
Soleus Capital Management LP 6.52 2,868,023 26.73 13F 9/30/21
BVF, Inc. 6.48 2,851,461 26.58 13F 9/30/21
RTW Investments LP 6.00 2,637,192 24.58 13F 9/30/21
Avidity Partners Management LP 5.57 2,450,000 22.83 13F 9/30/21
Eventide Asset Management LLC 4.96 2,181,101 20.33 13F 9/30/21
Adage Capital Partners GP LLC 3.51 1,542,531 14.38 13F 9/30/21
Vivo Capital LLC 2.40 1,056,067 9.84 13F 9/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.